Amico Pharma

Amico Pharma is an Indian pharmaceutical exporter specializing in the manufacture and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established by an award-winning entrepreneur, the company has been operational since 2001, focusing on providing high-quality medicines to various international markets. Its product portfolio encompasses a wide range of therapeutic categories, such as antibiotics, antimalarials, anti-cancer agents, NSAIDs, CNS drugs, cardiovascular medications, antifungals, and liquid injectables. These products are available in various dosage forms, including capsules, tablets, liquid orals, injectables, and ointments.

The company's manufacturing facilities adhere to international standards, with a WHO GMP certification ensuring the quality and reliability of its products. Amico Pharma's mission is to offer quality medicines at affordable prices, thereby improving human lives globally. The company has a significant presence in markets across Africa, Latin America, and parts of Asia, supplying products to hospitals, pharmacies, chemists, pharmaceutical wholesalers, health organizations, and medical centers.

Amico Pharma operates state-of-the-art manufacturing facilities that comply with international standards, including WHO GMP certification. These facilities are equipped to produce a diverse range of pharmaceutical formulations, ensuring high-quality products for global markets. The company's manufacturing capabilities include the production of tablets, capsules, liquid orals, injectables, and ointments, catering to various therapeutic categories.

Specific details regarding the current CEO, CFO, and other key executives of Amico Pharma are not publicly disclosed. The company's leadership comprises highly qualified and experienced professionals from the pharmaceutical industry, who adhere to stringent production standards to ensure product quality. The team includes skilled technical professionals from the production floor to marketing executives, forming the backbone of Amico Pharma.

Amico Pharma's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's focus has been on expanding into South and Central America, increasing its presence in brand marketing in West Africa, and exploring operations in CIS and Eastern European markets. However, specific regulatory filings, approvals, and market access statuses in these regions are not provided in the available information.

Amico Pharma has made significant inroads into emerging markets, particularly in Africa, Latin America, and parts of Asia. The company's expansion strategy includes increasing its presence in brand marketing in West Africa and exploring operations in CIS and Eastern European markets. While the available information does not specify WHO prequalification status, the company's adherence to WHO GMP standards suggests a commitment to meeting international quality benchmarks, which is crucial for accessing and expanding in these emerging markets.

Amico Pharma's geographic strategy demonstrates a focused approach to market expansion. By targeting regions such as South and Central America, West Africa, and parts of Asia, the company aims to diversify its market presence and reduce dependence on any single region. This strategy mitigates concentration risk and positions Amico Pharma to leverage growth opportunities in emerging markets. The company's commitment to quality and affordability aligns with the healthcare needs of these regions, supporting its strategic direction.

Specific details regarding Amico Pharma's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's focus has been on expanding into markets such as South and Central America, West Africa, and parts of Asia. While the available information does not provide insights into FDA approvals or inspections, the company's adherence to WHO GMP standards indicates a commitment to maintaining high-quality manufacturing practices.

Amico Pharma's manufacturing facilities are WHO GMP certified, ensuring that its products meet international quality standards. However, specific details regarding EU GMP certificates and EDQM status are not provided in the available sources. The company's adherence to WHO GMP standards underscores its commitment to producing high-quality pharmaceutical formulations for global markets.

Specific details regarding Amico Pharma's CDSCO manufacturing licenses, state drug controller approvals, and export NOCs are not publicly disclosed. The company's focus has been on expanding into international markets, including South and Central America, West Africa, and parts of Asia. While the available information does not provide insights into Indian regulatory approvals, the company's adherence to WHO GMP standards suggests compliance with international manufacturing practices.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Amico Pharma. The company's adherence to WHO GMP standards and its focus on quality manufacturing practices indicate a proactive approach to regulatory compliance. However, specific details regarding any regulatory actions are not provided in the available sources.

Amico Pharma operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific competitors are not identified in the available information, the company's focus on quality, affordability, and adherence to international standards positions it favorably in the market. The company's expansion into emerging markets and its diverse product portfolio further enhance its competitive standing.

Amico Pharma's key differentiators include its commitment to quality, as evidenced by its WHO GMP certification, and its focus on providing affordable medicines to a wide range of therapeutic categories. The company's strategic expansion into emerging markets and its diverse product portfolio further distinguish it in the pharmaceutical export sector.

Amico Pharma's current strategic direction focuses on expanding its presence in emerging markets, including South and Central America, West Africa, and parts of Asia. The company's adherence to WHO GMP standards and its commitment to quality manufacturing practices support its strategic objectives. Future outlooks suggest continued growth and diversification, leveraging the company's strengths in quality production and market expansion.

Amico Pharma has a track record of supplying a diverse range of pharmaceutical formulations to international markets. The company's export volume and consistency are supported by its adherence to WHO GMP standards and its focus on quality manufacturing practices. Reliability indicators include the company's strategic expansion into emerging markets and its commitment to providing affordable medicines across various therapeutic categories.

Importers should verify the following certifications when considering Amico Pharma as a supplier:

• WHO GMP Certification: Ensures compliance with international manufacturing standards. Verification can be done through the World Health Organization's official website or by contacting Amico Pharma directly.

• EU GMP Certification: Indicates adherence to European manufacturing standards. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to Amico Pharma.

• FDA Registration: Confirms approval for exporting to the United States. Verification can be performed through the U.S. Food and Drug Administration's official website or by contacting Amico Pharma.

When conducting due diligence on Amico Pharma, consider the following steps:

• Verify Certifications: Confirm WHO GMP, EU GMP, and FDA certifications as outlined above.

• Assess Regulatory Compliance: Review any available records of regulatory actions, such as warning letters or import alerts.

• Evaluate Financial Stability: Analyze financial statements and credit reports to assess the company's financial health.

• Review Product Portfolio: Examine the range and quality of products offered to ensure they meet your requirements.

• Conduct Site Visits: If possible, visit manufacturing facilities to assess compliance with quality standards.

Be cautious of any discrepancies in certification dates or regulatory compliance records, as these may indicate potential issues.